Clinical Trial Update: Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating neoadjuvant chemoradiotherapy plus tislelizumab with or without Probio-M9 in mismatch repair-proficient/microsatellite-stable locally…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Probio-M9
• Tyvyt (Sintilimab)

Snippet

Sponsor: Seventh Medical Center of PLA General Hospital | Conditions: Rectal Cancer, Adenocarcinoma, Neoadjuvant Therapy | Phase 2 | Status: RECRUITING